285 related articles for article (PubMed ID: 3278798)
1. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
[TBL] [Abstract][Full Text] [Related]
3. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
4. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group].
Rinsho Ketsueki; 1989 Jul; 30(7):967-74. PubMed ID: 2681882
[TBL] [Abstract][Full Text] [Related]
7. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
[TBL] [Abstract][Full Text] [Related]
8. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
[TBL] [Abstract][Full Text] [Related]
9. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A
J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717
[TBL] [Abstract][Full Text] [Related]
10. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T
Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
[TBL] [Abstract][Full Text] [Related]
11. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
Bleyer WA; Sather HN; Nickerson HJ; Coccia PF; Finklestein JZ; Miller DR; Littman PS; Lukens JN; Siegel SE; Hammond GD
J Clin Oncol; 1991 Jun; 9(6):1012-21. PubMed ID: 2033414
[TBL] [Abstract][Full Text] [Related]
12. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study.
Sullivan MP; Chen T; Dyment PG; Hvizdala E; Steuber CP
Blood; 1982 Oct; 60(4):948-58. PubMed ID: 6956376
[TBL] [Abstract][Full Text] [Related]
13. Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: A Report from Children's Cancer Study Group.
Nesbit ME; Sather H; Robison LL; Donaldson M; Littman P; Ortega JA; Hammond GD
Cancer Res; 1982 Feb; 42(2):674-80. PubMed ID: 7034927
[TBL] [Abstract][Full Text] [Related]
14. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Leikin SL; Albo VC; Sather H; Hammond GD
J Clin Oncol; 1989 Mar; 7(3):316-25. PubMed ID: 2645385
[TBL] [Abstract][Full Text] [Related]
15. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
[TBL] [Abstract][Full Text] [Related]
16. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
17. Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood.
Chessells JM; Durrant J; Hardy RM; Richards S
J Clin Oncol; 1986 Dec; 4(12):1758-64. PubMed ID: 3537216
[TBL] [Abstract][Full Text] [Related]
18. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
19. [Acute lymphoblastic leukemia in children. Long survivals obtained with protocols C2-72 and D-74 (1972-1977)].
Ortega JJ; Javier G; Montagut JM; Torán N
An Esp Pediatr; 1986 Feb; 24(2):87-97. PubMed ID: 3516041
[TBL] [Abstract][Full Text] [Related]
20. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
